Modelling psychosis

被引:7
作者
Curran, H. Valerie [1 ]
D'Souza, Deepak Cyril [3 ]
Robbins, Trevor W. [4 ]
Fletcher, Paul [2 ]
机构
[1] UCL, Clin Psychopharmacol Unit, London WC1E 6BT, England
[2] Univ Cambridge, Addenbrookes Hosp, Dept Psychiat, Cambridge CB2 2QQ, England
[3] Yale Univ, Sch Med, New Haven, CT USA
[4] Univ Cambridge, Dept Expt Psychol, Cambridge CB2 3EB, England
基金
英国惠康基金; 英国医学研究理事会;
关键词
D O I
10.1007/s00213-009-1663-8
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
引用
收藏
页码:513 / 514
页数:2
相关论文
共 6 条
[1]  
[Anonymous], 1980, LSD: My Problem Child
[2]  
Huxley A., 1954, DOORS PERCEPTION
[3]  
Moreau J.J., 1845, Hashish and Mental Illness
[4]   A REVIEW OF THE CLINICAL EFFECTS OF PSYCHOTOMIMETIC AGENTS [J].
OSMOND, H .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1957, 66 (03) :418-434
[5]   Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial [J].
Patil, Sandeep T. ;
Zhang, Lu ;
Martenyi, Ferenc ;
Lowe, Stephen L. ;
Jackson, Kimberley A. ;
Andreev, Boris V. ;
Avedisova, Alla S. ;
Bardenstein, Leonid M. ;
Gurovich, Issak Y. ;
Morozova, Margarita A. ;
Mosolov, Sergey N. ;
Neznanov, Nikolai G. ;
Reznik, Alexander M. ;
Smulevich, Anatoly B. ;
Tochilov, Vladimir A. ;
Johnson, Bryan G. ;
Monn, James A. ;
Schoepp, Darryle D. .
NATURE MEDICINE, 2007, 13 (09) :1102-1107
[6]   Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug [J].
Zuardi, AW ;
Crippa, JAS ;
Hallak, JEC ;
Moreira, FA ;
Guimaraes, FS .
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2006, 39 (04) :421-429